Jinghe Ye, Mao Wu, Long He, Peng Chen, Hongtao Liu, Hongwei Yang
{"title":"无细胞DNA谷胱甘肽- s -转移酶p1基因启动子甲基化作为前列腺癌的诊断和预后工具:系统回顾和荟萃分析","authors":"Jinghe Ye, Mao Wu, Long He, Peng Chen, Hongtao Liu, Hongwei Yang","doi":"10.1155/2023/7279243","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Promoter methylation of glutathione-S-transferase <i>p</i>1 (GSTP1) is related to the occurrence of prostate cancer (PCa), but reports are inconsistent about the accuracy of GSTP1 promoter methylation in PCa diagnosis and prognosis. Therefore, we systematically evaluated the diagnostic and prognostic value of GSTP1 promoter methylation in PCa.</p><p><strong>Methods: </strong>The PubMed, EMBASE, Web of Science, and PMC databases were searched for all relevant studies from the date of inception to November 31, 2021. We compared differences in the incidence of GSTP1 promoter methylation in cfDNA between prostate cancer patients and controls. The odds ratio (OR) and hazard ratio (HR) were used as effect sizes, and the result of each effect size is expressed as a 95% confidence interval (95% CI).</p><p><strong>Results: </strong>Our meta-analysis showed that the combined sensitivity and specificity of GSTP1 promoter methylation in cfDNA for the diagnosis of prostate cancer were 0.37 (95% CI = 0.23, 0.53) and 0.97 (95% CI = 0.88, 0.99), respectively. The area under the curve (AUC) with 95% CI was 0.78 (95% CI = 0.75, 0.82). For prognostic variables, hypermethylation of GSTP1 was associated with shorter survival in PCa (HR = 2.57, 95% CI = 1.30, 5.10), with statistical significance in between-study heterogeneity (<i>I</i> <sup>2</sup> = 72%, <i>P</i>=0.006). The results of the subgroup analysis indicated that the heterogeneity of studies may be due to differences in the observed indicators.</p><p><strong>Conclusions: </strong>The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899149/pdf/","citationCount":"1","resultStr":"{\"title\":\"Glutathione-S-Transferase <i>p</i>1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis.\",\"authors\":\"Jinghe Ye, Mao Wu, Long He, Peng Chen, Hongtao Liu, Hongwei Yang\",\"doi\":\"10.1155/2023/7279243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Promoter methylation of glutathione-S-transferase <i>p</i>1 (GSTP1) is related to the occurrence of prostate cancer (PCa), but reports are inconsistent about the accuracy of GSTP1 promoter methylation in PCa diagnosis and prognosis. Therefore, we systematically evaluated the diagnostic and prognostic value of GSTP1 promoter methylation in PCa.</p><p><strong>Methods: </strong>The PubMed, EMBASE, Web of Science, and PMC databases were searched for all relevant studies from the date of inception to November 31, 2021. We compared differences in the incidence of GSTP1 promoter methylation in cfDNA between prostate cancer patients and controls. The odds ratio (OR) and hazard ratio (HR) were used as effect sizes, and the result of each effect size is expressed as a 95% confidence interval (95% CI).</p><p><strong>Results: </strong>Our meta-analysis showed that the combined sensitivity and specificity of GSTP1 promoter methylation in cfDNA for the diagnosis of prostate cancer were 0.37 (95% CI = 0.23, 0.53) and 0.97 (95% CI = 0.88, 0.99), respectively. The area under the curve (AUC) with 95% CI was 0.78 (95% CI = 0.75, 0.82). For prognostic variables, hypermethylation of GSTP1 was associated with shorter survival in PCa (HR = 2.57, 95% CI = 1.30, 5.10), with statistical significance in between-study heterogeneity (<i>I</i> <sup>2</sup> = 72%, <i>P</i>=0.006). The results of the subgroup analysis indicated that the heterogeneity of studies may be due to differences in the observed indicators.</p><p><strong>Conclusions: </strong>The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.</p>\",\"PeriodicalId\":13966,\"journal\":{\"name\":\"International Journal of Endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899149/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/7279243\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/7279243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 1
摘要
背景:谷胱甘肽- s -转移酶p1 (GSTP1)启动子甲基化与前列腺癌(PCa)的发生有关，但GSTP1启动子甲基化在前列腺癌诊断和预后中的准确性报道不一致。因此，我们系统地评估了GSTP1启动子甲基化在前列腺癌中的诊断和预后价值。方法:检索PubMed、EMBASE、Web of Science和PMC数据库从建库日期到2021年11月31日的所有相关研究。我们比较了前列腺癌患者和对照组之间cfDNA中GSTP1启动子甲基化发生率的差异。使用优势比(OR)和风险比(HR)作为效应量，每个效应量的结果用95%置信区间(95% CI)表示。结果:我们的荟萃分析显示，cfDNA中GSTP1启动子甲基化诊断前列腺癌的综合敏感性和特异性分别为0.37 (95% CI = 0.23, 0.53)和0.97 (95% CI = 0.88, 0.99)。曲线下面积(AUC) 95% CI为0.78 (95% CI = 0.75, 0.82)。对于预后变量，GSTP1的高甲基化与PCa患者较短的生存期相关(HR = 2.57, 95% CI = 1.30, 5.10)，研究间异质性具有统计学意义(I 2 = 72%， P=0.006)。亚组分析的结果表明，研究的异质性可能是由于观察指标的差异。结论:荟萃分析结果证实cfDNA中GSTP1启动子甲基化对前列腺癌的诊断具有高特异性，可用于更准确地评估前列腺癌患者的预后。它可能有助于前列腺癌的早期检测，但它仍然必须与传统的前列腺特异性抗原(PSA)或其他甲基化基因结合才能实现这一目标。
Glutathione-S-Transferase p1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis.
Background: Promoter methylation of glutathione-S-transferase p1 (GSTP1) is related to the occurrence of prostate cancer (PCa), but reports are inconsistent about the accuracy of GSTP1 promoter methylation in PCa diagnosis and prognosis. Therefore, we systematically evaluated the diagnostic and prognostic value of GSTP1 promoter methylation in PCa.
Methods: The PubMed, EMBASE, Web of Science, and PMC databases were searched for all relevant studies from the date of inception to November 31, 2021. We compared differences in the incidence of GSTP1 promoter methylation in cfDNA between prostate cancer patients and controls. The odds ratio (OR) and hazard ratio (HR) were used as effect sizes, and the result of each effect size is expressed as a 95% confidence interval (95% CI).
Results: Our meta-analysis showed that the combined sensitivity and specificity of GSTP1 promoter methylation in cfDNA for the diagnosis of prostate cancer were 0.37 (95% CI = 0.23, 0.53) and 0.97 (95% CI = 0.88, 0.99), respectively. The area under the curve (AUC) with 95% CI was 0.78 (95% CI = 0.75, 0.82). For prognostic variables, hypermethylation of GSTP1 was associated with shorter survival in PCa (HR = 2.57, 95% CI = 1.30, 5.10), with statistical significance in between-study heterogeneity (I2 = 72%, P=0.006). The results of the subgroup analysis indicated that the heterogeneity of studies may be due to differences in the observed indicators.
Conclusions: The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.
期刊介绍：
International Journal of Endocrinology is a peer-reviewed, Open Access journal that provides a forum for scientists and clinicians working in basic and translational research. The journal publishes original research articles, review articles, and clinical studies that provide insights into the endocrine system and its associated diseases at a genomic, molecular, biochemical and cellular level.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
